About the Rare Disease COA Consortium
Our Vision
To be an essential catalyst in medical product development for measuring what matters to people with rare diseases.
Our Mission
To enable precompetitive, multi-stakeholder collaboration aimed at identifying scientifically sound tools and methodologies for collecting clinically meaningful outcomes data in treatment trials for rare diseases.
Scientific Strategy
- Expand the Rare Disease Clinical Outcome Assessment (COA) Resource into new domains of published COAs that have the potential to be used to support efficacy endpoints in treatment trials for rare diseases;
- Promote collaboration and education, and share learnings among member firms and consortium members to expedite innovations in rare clinical trial science; and
- Advance solutions for methodological and measurement challenges in rare disease by engaging teams of experts focused on dissemination.
Acknowledgement of Federal Support
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 43% funded by the FDA/HHS, totaling $20,724,703, and 57% funded by non-government source(s), totaling $27,346,613. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
Funding for the establishment of the Rare Disease COA Consortium was made possible, in part, by the Food and Drug Administration through grant (U01FD006).
Contact
For questions or additional information about membership in the Rare Disease COA Consortium, please visit https://c-path.org/programs/rd-coac/ or contact Lindsey Murray at lmurray@c-path.org
Inquiries regarding updates to the Rare Disease COA Resource can be sent to coapadmin@c-path.org